Actively Recruiting
Liposomal Bupivacaine Versus Ropivacaine for Preperitoneal Infiltration Analgesia in Upper Abdominal Laparotomy
Led by Qilu Hospital of Shandong University · Updated on 2026-02-27
146
Participants Needed
1
Research Sites
21 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Upper abdominal open surgery is associated with significant trauma, and postoperative pain management poses considerable challenges. The inflammatory response triggered by peritoneal incision and the transmission of visceral pain via the vagus nerve are key components of "surgical stress" and pain. A potential intervention strategy involves the local administration of anesthetic agents to suppress peritoneal overreaction and block the cascade of pro-inflammatory cytokines in related nerves. Liposomal bupivacaine, as a long-acting local anesthetic, may provide more prolonged postoperative analgesia compared to ropivacaine. Therefore, this trial aims to prospectively compare the analgesic efficacy and anti-inflammatory effects of the two drugs when administered as pre-closure preperitoneal infiltration. Secondary endpoints include opioid consumption, complication rates, and postoperative recovery indicators, to comprehensively evaluate their clinical value.
CONDITIONS
Official Title
Liposomal Bupivacaine Versus Ropivacaine for Preperitoneal Infiltration Analgesia in Upper Abdominal Laparotomy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 75 years; for those over 70 years old, a Karnofsky Performance Status score of 80 or higher is required
- Scheduled for elective upper abdominal laparotomy
- Surgical incision is either subcostal or midline
- Incision length between 15 and 30 centimeters
- American Society of Anesthesiologists physical status classification of I to III
You will not qualify if you...
- ASA Physical Status Class greater than III
- Long-term opioid use for chronic pain lasting more than 1 year
- Significant liver or kidney problems or underweight status, including eGFR less than 40 mL/min/1.73m², Child-Pugh Class C, or BMI under 18.5 kg/m²
- Known allergy or sensitivity to the study drug or its ingredients
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Qilu Hospital of Shandong University
Jinan, China
Actively Recruiting
Research Team
J
Jinying Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here